Does addition of pramlintide to basal insulin improve glycemic control in type 2 diabetes mellitus?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 4, 2008, Pages 194-195

  Edelman, Steven V ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Glycemic control; HbA1c; Insulin; Pramlintide; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE;

ADULT; AGE DISTRIBUTION; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 41149143605     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0760     Document Type: Note

References (4)

1. Edelman SV and Henry RR (2006) Diagnosis and management of type 2 diabetes, edn 7, 237-252. Greenwich, CT: Professional Communications Inc.
2. Hollander PA et al. (2003) Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26: 784-790
3. Hollander P et al. (2004) Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12: 661-668
4. Edelman SV et al. (2006) Pramlintide in the treatment of diabetes. Int J Clin Pract 60: 1647-1653